Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent subunit influenza vaccine (Beijing Baihui Biotechnology)
- Development stage
- Unknown
- Lead developer
- Beijing Baihui Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The trivalent subunit influenza vaccine is a seasonal prophylactic vaccine designed to protect against three strains of the influenza virus. Unlike whole-virus or split-virion vaccines, subunit vaccines contain only highly purified viral surface proteins—specifically hemagglutinin (HA) and neuraminidase (NA)—which are the primary targets for neutralizing antibodies. This purification process is intended to minimize the presence of internal viral proteins and host-cell contaminants, potentially leading to a better safety profile and lower reactogenicity. The specific candidate mentioned in the context is being developed by Beijing Baihui Biotechnology and Bohui Biopharmaceutical. It is currently in Phase I clinical trials in China (CTR20254002), where it is being evaluated for safety and immunogenicity in a population aged 3 years and older using both single and two-dose immunization schedules.
- Other names
- trivalent influenza subunit vaccinetrivalent subunit flu vaccine
02
Targets
BCR-NA (B-cell receptor specific for influenza neuraminidase)BCR (B-cell receptor (BCR) specific for influenza hemagglutinin epitopes)CD4+ T-cell receptor recognizing influenza hemagglutinin-derived peptides presented on MHC class II
Beyond the preview
Go deeper on trivalent subunit influenza vaccine (Beijing Baihui Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent subunit influenza vaccine (Beijing Baihui Biotechnology).